.jpg?format=webp&width=780)
This study assessed the effect of darolutamide on urinary and bowel symptoms. Fewer patients receiving darolutamide (4.7%) versus placebo (9.6%) underwent invasive procedures, and time to the first procedure was prolonged with darolutamide. Darolutamide demonstrated a positive impact on local disease recurrence and symptom control in patients with nmCRPC, delayed time to deterioration in QoL related to urinary and bowel symptoms, and a favourable safety profile showing a similar incidence of urinary‐ and bowel‐related adverse events compared with placebo.
Like
Save
Share